Drug Profile
Research programme: CSF-1 receptor antagonists/FMS-like tyrosine kinase inhibitors - Johnson & Johnson
Alternative Names: CSF1-1R antagonists; FMS kinase inhibitors; JNJ-28312141Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Johnson & Johnson
- Class Nitriles; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Macrophage colony stimulating factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Rheumatoid arthritis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 01 Mar 2011 No development reported - Preclinical for Rheumatoid arthritis in USA (unspecified route)
- 02 Sep 2008 Preclinical trials in Rheumatoid arthritis in USA (unspecified route)